{"id":"ba3bc9099340","type":"article","url":"https://hartvaat.nl/2026/11/12/sglt2-remmers-gekoppeld-aan-minder-ascites-bij-cirrose-met-diabetes-retrospectie/","title":"SGLT2-remmers gekoppeld aan minder ascites bij cirrose met diabetes — retrospectief cohort","title_en":"Baseline SGLT2 inhibitor use and documented ascites after a first ascites hospitalization: a retrospective two-center cohort study.","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","internist"],"tags":[],"journal":"Revista espanola de enfermedades digestivas","doi":"10.17235/reed.2026.12277/2026","source_url":"https://doi.org/10.17235/reed.2026.12277/2026","authors":["Daniel Riado Mínguez","Francisco Javier Parra Villanueva","Alejandra Cristina Rodríguez Heinsen","Flor M ª Fernández-Gordón Sánchez","Sandra Agudo Fernández","Cristina Cuadrado Tiemblo","Alicia Bejerano Domínguez","Carlos Castaño Milla"],"significance":3,"published":"2026-11-20","source_date":"2026-11-12","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/digoxine-bij-hartfalen/","https://hartvaat.nl/kennis/farmacologie/antiaritmica-farmacologie/"],"congress":"","summary_en":"In a retrospective two-center cohort of 103 patients with cirrhosis and type 2 diabetes admitted for first-onset ascites, baseline SGLT2 inhibitor use was associated with a lower rate of documented ascites during follow-up (50% vs 80.3%; adjusted OR 0.23). While hospitalization rates, survival, and renal function did not differ between groups, the findings suggest a potential role for SGLT2 inhibitors in managing fluid retention in decompensated cirrhosis. Prospective trials are needed to confirm efficacy and safety in this population.","created":"2026-11-13T02:39:38Z","updated":"2026-11-13T02:39:38Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"In een retrospectief tweecentrumcohort van 103 patiënten met cirrose en type 2-diabetes die voor het eerst met ascites werden opgenomen, bleek voorafgaand gebruik van SGLT2-remmers geassocieerd met een lager percentage gedocumenteerd ascites tijdens follow-up (50% versus 80,3%; aOR 0,23). Hoewel er geen verschil was in ziekenhuisopnames, overleving of nierfunctie, suggereert dit dat SGLT2-remmers mogelijk een rol kunnen spelen in het beheer van vochthouding bij deze kwetsbare groep. Voorlopig zijn prospectieve studies nodig om de effectiviteit en veiligheid te bevestigen.","abstract_original":"INTRODUCTION: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) may benefit fluid retention in cirrhosis, but evidence in decompensated patients remains limited. We evaluated the association between SGLT2i and documented ascites during follow-up in patients with cirrhosis and type 2 diabetes mellitus (T2DM) after a first episode of ascites. METHODS: A two-center retrospective cohort study of patients with cirrhosis and T2DM hospitalized for a first episode of ascites between 2017 and 2025 in Spain. Patients were classified according to SGLT2i use before admission. The primary endpoint was the presence of documented ascites at scheduled follow-up assessments after discharge. Secondary outcomes included relevant clinical and biochemical outcomes. RESULTS: Among 103 patients, 27 (26.2%) received SGLT2i and 76 (73.8%) did not. Median follow-up was 52 weeks [26-104]. SGLT2i users had a lower proportion of documented ascites (13/26 vs 53/66; 50% vs 80.3%; p=0.004). This association persisted after adjustment for potential confounders (aOR 0.23, 95% CI 0.08-0.66; p=0.006), with consistent results in a 6-month sensitivity analysis. No significant differences were observed in hospitalizations for ascites, for overall liver decompensation, LVPs, RA, hepatic encephalopathy, acute kidney injury or survival. Serum creatinine and sodium did not show differences between groups. 5/27 (18.5%) patients discontinued treatment. CONCLUSIONS: SGLT2i use was associated with a lower proportion of documented ascites after a first episode. Prospective studies are needed to establish their efficacy and safety in decompensated cirrhosis."}